Alto Neuroscience (ANRO) Stock Forecast, Price Target & Predictions
ANRO Stock Forecast
Alto Neuroscience (ANRO) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $30.75, with a high of $36.00 and a low of $24.00. This represents a 42.76% increase from the last price of $21.54.
ANRO Stock Rating
Alto Neuroscience stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (87.50%), 1 Hold (12.50%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).
Buy
ANRO Price Target Upside V Benchmarks
| Type | Name | Upside |
|---|---|---|
| Stock | Alto Neuroscience | 42.76% |
| Sector | Healthcare Stocks | 15.45% |
| Industry | Biotech Stocks | 41.48% |
Price Target Trends
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 3 | 5 |
| Avg Price Target | $30.00 | $31.67 | $27.80 |
| Last Closing Price | $21.54 | $21.54 | $21.54 |
| Upside/Downside | 39.28% | 47.03% | 29.06% |
Ratings Trends
| Date | Strong Buy | Buy | Hold | Sell | Strong Sell | Total |
|---|---|---|---|---|---|---|
| May, 26 | - | 9 | 1 | - | - | 10 |
| Apr, 26 | - | 9 | 1 | - | - | 10 |
| Mar, 26 | - | 9 | 1 | - | - | 10 |
| Feb, 26 | - | 9 | 1 | - | - | 10 |
| Jan, 26 | - | 9 | 1 | - | - | 10 |
Analyst Price Target Forecasts
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 18, 2026 | Robert W. Baird | $36.00 | $22.98 | 56.66% | 67.13% | |
| May 14, 2026 | Laura Chico | Wedbush | $24.00 | $22.85 | 5.03% | 11.42% |
| Mar 16, 2026 | Andrew Tsai | Jefferies | $35.00 | $24.78 | 41.24% | 62.49% |
| Feb 17, 2026 | Thomas Shrader | BTIG | $28.00 | $16.89 | 65.78% | 29.99% |
| Oct 20, 2025 | Robert W. Baird | $16.00 | $11.07 | 44.53% | -25.72% | |
| Oct 23, 2024 | Brian Skorney | Robert W. Baird | $10.00 | $14.53 | -31.18% | -53.57% |
| Jun 20, 2024 | Brian Skorney | Robert W. Baird | $32.00 | $11.11 | 188.03% | 48.56% |
Analyst Rating Forecasts
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 22, 2026 | Wolfe Research | Outperform | initialise | |
| May 14, 2026 | Wedbush | Neutral | Neutral | hold |
| Mar 16, 2026 | Jefferies | Buy | Buy | hold |
| Feb 17, 2026 | BTIG | Buy | Buy | hold |
| Oct 23, 2024 | Wedbush | Outperform | Neutral | downgrade |
| Oct 23, 2024 | Rodman & Renshaw | Buy | Neutral | downgrade |
| Sep 10, 2024 | Cowen & Co. | Buy | Buy | hold |
| Sep 03, 2024 | Wedbush | Outperform | initialise | |
| Jun 20, 2024 | Rodman & Renshaw | Buy | initialise |
Financial Forecast
EPS Forecast
Annual
| Dec 23 | Dec 24 | Dec 25 | Dec 26 | Dec 27 | Dec 28 | |
|---|---|---|---|---|---|---|
| Reported | $-1.35 | $-2.50 | $-2.19 | - | - | - |
| Avg Forecast | $-2.93 | $-2.59 | $-2.53 | $-2.73 | $-2.52 | $-2.80 |
| High Forecast | $-2.93 | $-2.41 | $-2.24 | $-2.22 | $-2.23 | $-2.80 |
| Low Forecast | $-2.93 | $-2.75 | $-2.95 | $-3.38 | $-2.67 | $-2.80 |
| Surprise % | -53.92% | -3.47% | -13.44% | - | - | - |
Revenue Forecast
Annual
| Dec 23 | Dec 24 | Dec 25 | Dec 26 | Dec 27 | Dec 28 | |
|---|---|---|---|---|---|---|
| Reported | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | $10.02M | $2.27M |
| High Forecast | - | - | - | - | $10.02M | $2.27M |
| Low Forecast | - | - | - | - | $10.02M | $2.27M |
| Surprise % | - | - | - | - | - | - |
Net Income Forecast
Annual
| Dec 23 | Dec 24 | Dec 25 | Dec 26 | Dec 27 | Dec 28 | |
|---|---|---|---|---|---|---|
| Reported | $-36.30M | $-61.43M | $-63.24M | - | - | - |
| Avg Forecast | $-78.64M | $-69.39M | $-77.05M | $-75.32M | $-65.84M | $-75.21M |
| High Forecast | $-78.64M | $-64.87M | $-60.12M | $-59.78M | $-59.90M | $-75.21M |
| Low Forecast | $-78.64M | $-73.90M | $-79.21M | $-90.86M | $-71.77M | $-75.21M |
| Surprise % | -53.83% | -11.47% | -17.93% | - | - | - |